Latest news
Forlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia - BioSpaceBioSpace · Wed, 05 Aug 2026 03:09:14 GMTAdlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock TitanStock Titan · Mon, 03 Aug 2026 12:00:53 GMTAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 11:19:31 GMT